ENTA
Price
$5.46
Change
-$0.14 (-2.50%)
Updated
Apr 24, 02:24 PM (EDT)
Capitalization
117.33M
18 days until earnings call
PRME
Price
$1.74
Change
-$0.04 (-2.25%)
Updated
Apr 24, 02:44 PM (EDT)
Capitalization
221.66M
15 days until earnings call
Ad is loading...

ENTA vs PRME

Header iconENTA vs PRME Comparison
Open Charts ENTA vs PRMEBanner chart's image
Enanta Pharmaceuticals
Price$5.46
Change-$0.14 (-2.50%)
Volume$100
Capitalization117.33M
Prime Medicine
Price$1.74
Change-$0.04 (-2.25%)
Volume$100
Capitalization221.66M
ENTA vs PRME Comparison Chart
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. PRME commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and PRME is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (ENTA: $5.60 vs. PRME: $1.76)
Brand notoriety: ENTA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 45% vs. PRME: 182%
Market capitalization -- ENTA: $117.33M vs. PRME: $221.66M
ENTA [@Biotechnology] is valued at $117.33M. PRME’s [@Biotechnology] market capitalization is $221.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • ENTA’s TA Score: 5 bullish, 5 bearish.
  • PRME’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ENTA and PRME are a good buy in the short-term.

Price Growth

ENTA (@Biotechnology) experienced а +13.59% price change this week, while PRME (@Biotechnology) price change was +41.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

ENTA is expected to report earnings on Aug 11, 2025.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($222M) has a higher market cap than ENTA($117M). ENTA YTD gains are higher at: -2.609 vs. PRME (-39.726). ENTA has higher annual earnings (EBITDA): -94.42M vs. PRME (-196.34M). ENTA has more cash in the bank: 217M vs. PRME (190M). PRME has less debt than ENTA: PRME (40.8M) vs ENTA (57.5M). ENTA has higher revenues than PRME: ENTA (66.6M) vs PRME (2.98M).
ENTAPRMEENTA / PRME
Capitalization117M222M53%
EBITDA-94.42M-196.34M48%
Gain YTD-2.609-39.7267%
P/E RatioN/AN/A-
Revenue66.6M2.98M2,233%
Total Cash217M190M114%
Total Debt57.5M40.8M141%
FUNDAMENTALS RATINGS
ENTA vs PRME: Fundamental Ratings
ENTA
PRME
OUTLOOK RATING
1..100
423
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
6593
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
n/a58

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (44) in the null industry is somewhat better than the same rating for ENTA (96) in the Biotechnology industry. This means that PRME’s stock grew somewhat faster than ENTA’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as ENTA (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (95) in the Biotechnology industry is in the same range as PRME (96) in the null industry. This means that ENTA’s stock grew similarly to PRME’s over the last 12 months.

ENTA's Price Growth Rating (65) in the Biotechnology industry is in the same range as PRME (93) in the null industry. This means that ENTA’s stock grew similarly to PRME’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for PRME (100) in the null industry. This means that ENTA’s stock grew significantly faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 17 days ago
83%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CDHRX31.06N/A
N/A
Calvert International Responsible Idx R6
MNSEF0.02N/A
N/A
Magnis Energy Technologies Ltd.
FSOPX12.63N/A
N/A
Fidelity Series Small Cap Opps
AQGRX10.43N/A
N/A
AQR Global Equity R6
PREKF17.06-0.06
-0.35%
Prairiesky Royalty Ltd.

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+1.82%
ALEC - ENTA
36%
Loosely correlated
+6.31%
BEAM - ENTA
36%
Loosely correlated
+3.87%
PRME - ENTA
36%
Loosely correlated
+4.14%
ABOS - ENTA
35%
Loosely correlated
+3.86%
CLRB - ENTA
35%
Loosely correlated
+2.48%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+4.14%
CRSP - PRME
63%
Loosely correlated
-1.76%
RXRX - PRME
59%
Loosely correlated
-0.89%
BEAM - PRME
58%
Loosely correlated
+3.87%
NTLA - PRME
57%
Loosely correlated
-2.65%
ABCL - PRME
53%
Loosely correlated
+0.79%
More